You are here

  • Home
  • Archive
  • Volume 9, Issue 1
  • Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer

Article info

Article menu

This article has a correction. Please see:

Clinical/translational cancer immunotherapy
Original research
Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer

Authors

  • Mohamed A Ghonim The Stanley Scott Cancer Center/Louisiana Cancer Research Center, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USADepartment of Microbiology and Immunology, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt PubMed articlesGoogle scholar articles
  • Salome V Ibba The Stanley Scott Cancer Center/Louisiana Cancer Research Center, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA PubMed articlesGoogle scholar articles
  • Abdelmetalab F Tarhuni The Stanley Scott Cancer Center/Louisiana Cancer Research Center, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA PubMed articlesGoogle scholar articles
  • Youssef Errami The Stanley Scott Cancer Center/Louisiana Cancer Research Center, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA PubMed articlesGoogle scholar articles
  • Hanh H Luu The Stanley Scott Cancer Center/Louisiana Cancer Research Center, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA PubMed articlesGoogle scholar articles
  • Matthew J Dean The Stanley Scott Cancer Center/Louisiana Cancer Research Center, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA PubMed articlesGoogle scholar articles
  • Ali H El-Bahrawy The Stanley Scott Cancer Center/Louisiana Cancer Research Center, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USADepartment of Pharmacology, Faculty of Pharmacy, Al- Azhar University, Assiut, Egypt PubMed articlesGoogle scholar articles
  • Dorota Wyczechowska The Stanley Scott Cancer Center/Louisiana Cancer Research Center, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA PubMed articlesGoogle scholar articles
  • Ilyes A Benslimane The Stanley Scott Cancer Center/Louisiana Cancer Research Center, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA PubMed articlesGoogle scholar articles
  • Luis Del Valle The Stanley Scott Cancer Center/Louisiana Cancer Research Center, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA PubMed articlesGoogle scholar articles
  • Amir A Al-Khami The Stanley Scott Cancer Center/Louisiana Cancer Research Center, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USAFaculty of Science, Tanta University, Tanta, Egypt PubMed articlesGoogle scholar articles
  • Augusto C Ochoa The Stanley Scott Cancer Center/Louisiana Cancer Research Center, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA PubMed articlesGoogle scholar articles
  • A Hamid Boulares The Stanley Scott Cancer Center/Louisiana Cancer Research Center, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA PubMed articlesGoogle scholar articles

Citation

Ghonim MA, Ibba SV, Tarhuni AF, et al
Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer
Journal for ImmunoTherapy of Cancer 2021;9:e001643. doi: 10.1136/jitc-2020-001643
Online issue publication 
November 23, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.